Post Stabilisation Notice - Nidda Healthcare FRN

UBS AG

15 November 2024

 

15^th November 2024

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Nidda Healthcare Holding GmbH
Post-Stabilisation Notice

UBS Investment Bank (contact: Debt Syndicate; telephone: [phone] hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority was undertaken by the Stabilising Manager named below in relation to the offer of the following securities.

Issuer:	Nidda Healthcare Holding GmbH
Guarantor (if any):	German Holdco, EG SA (formerly, Eurogenerics SA), Internis Pharmaceuticals Limited, Thornton & Ross Limited, STADA, Clonmel Healthcare Limited, Centrafarm B.V., Crosspharma Limited, Britannia Pharmaceuticals Limited and Natures Aid Ltd, collectively
Aggregate nominal amount:	EUR 600,000,000
Description:	Senior Secured Floating Rate Notes due 2030
Stabilising Manager(s)	UBS AG London Branch

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement is not an offer of securities for sale into the United States. The securities referred to above have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration.  There has not been and will not be a public offer of the securities in the United States.

 

END